Mounjaro vs Ozempic: Which Diabetes Drug Wins on A1C, Weight, and Cost (2026)
For type 2 diabetes, Mounjaro is the stronger glucose-lowering brand: it beat Ozempic head-to-head on A1C in a direct trial (SURPASS-2) and pushed more people to target. But "stronger A1C number" is not the whole decision, and Ozempic still wins on the deepest heart-protection evidence and on cost. This page answers the question two ways at once: what the diabetes trials actually show, and what the ProtocolPlus community does when it has been on both.
Mounjaro is tirzepatide; Ozempic is semaglutide. They are the two brands a clinician reaches for first when the diagnosis is type 2 diabetes, and most people who get one of them also lose weight, which is why the comparison feels bigger than diabetes alone and why it sits near the top of our guide to the best peptides for weight loss. Most "Mounjaro vs Ozempic" pages stop at a trial table. We add the signal no competitor has: among our users who logged both brands, which one people actually pick and which direction they switch. For the deep molecule science we link out so this page stays a clean diabetes-brand decision hub.
Head-to-head
Edge: TIE — effectively a tie
Mounjaro (tirzepatide) and Ozempic (semaglutide) are the two big type 2 diabetes brands, and Mounjaro is the stronger glucose-lowering molecule: in SURPASS-2, the only head-to-head diabetes trial, Mounjaro 15 mg cut A1C about 2.30 points versus 1.86 for Ozempic 1 mg, and 79% reached A1C under 7% versus 64%. Ozempic answers back with the deeper cardiovascular-outcomes track record (the SUSTAIN-6 25% reduction in major cardiac events) and a lower per-dose cost. The headline signal on this page is the ProtocolPlus community moat: which brand people on these drugs actually pick and switch toward, with the fit-score radar as the secondary editorial 'why'.
Overall fit score
By dimension
Side by side
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand (this page) | Ozempic | Mounjaro |
| Active molecule | Semaglutide (GLP-1 agonist) | Tirzepatide (dual GIP + GLP-1 agonist) |
| Maker | Novo Nordisk | Eli Lilly |
| FDA approval for type 2 diabetes | 2017 | May 2022 |
| A1C reduction, head-to-head (SURPASS-2, 40 wk) | -1.86 points (1 mg) | -2.30 points (15 mg) |
| Reached A1C under 7% (SURPASS-2) | 64% | 79% |
| Weight change in that diabetes trial | -6.2 kg | -12.4 kg |
| Cardiovascular-outcomes indication | Yes (CV-risk reduction, SUSTAIN-6) | Not yet (CV trial ongoing) |
| Top maintenance dose | 2 mg weekly | 15 mg weekly |
| Community median cost / dose | $19 | $56 |
| Most-reported side effect (community) | Nausea 44% | Nausea 42% |
Educational. Both are FDA-approved prescription medicines; this is not medical advice, not a dose recommendation, and not a claim that either brand is better for you. Community usage/switch figures are illustrative ProtocolPlus app data. Verify everything with a clinician.
Key Takeaways
- Better A1C lowering: Mounjaro. In SURPASS-2, the only head-to-head diabetes trial, Mounjaro 15 mg cut A1C about 2.30 points versus 1.86 for Ozempic 1 mg over 40 weeks, and 79% of Mounjaro patients reached A1C under 7% versus 64% on Ozempic.
- Why Mounjaro pulls ahead: it is a dual GIP and GLP-1 receptor agonist, while Ozempic acts on GLP-1 alone. Two metabolic pathways instead of one.
- Weight comes along with the diabetes control. In that same diabetes trial, Mounjaro 15 mg dropped about 12.4 kg versus 6.2 kg for Ozempic, so people typically lose roughly twice as much weight while treating their blood sugar.
- Ozempic still wins on two things: the deepest cardiovascular-outcomes evidence (the SUSTAIN-6 trial cut major cardiac events about 26%) and cost (median $19 vs $56 per dose in our community data).
- What our community does: among ProtocolPlus users tracking these two, the split is roughly 45% Ozempic, 55% Mounjaro, and the net switch runs toward Mounjaro about 2.5 to 1. A usage signal, not proof one is better for you.
- Both are FDA-approved for type 2 diabetes: Ozempic since 2017 (with an added cardiovascular-risk indication), Mounjaro since May 2022. Coverage usually hinges on the diabetes diagnosis.
Mounjaro vs Ozempic at a glance
Here is the side-by-side before we go deep. Mounjaro leads on raw glucose and weight control; Ozempic leads on heart-outcomes history and price. Everything below this table explains the why.
| Dimension | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Maker | Novo Nordisk | Eli Lilly |
| FDA-approved for type 2 diabetes | 2017 | May 2022 |
| A1C reduction, head-to-head (SURPASS-2) | -1.86 (1 mg) | -2.30 (15 mg) |
| Reached A1C under 7% (SURPASS-2) | 64% | 79% |
| Weight change in that diabetes trial | -6.2 kg | -12.4 kg |
| Cardiovascular-outcomes indication | Yes (SUSTAIN-6) | Not yet |
| Top maintenance dose | 2 mg weekly | 15 mg weekly |
| Community median cost / dose | $19 | $56 |
| Nausea (our community reports) | 44% | 42% |
The table is the headline. The two places the answer genuinely flips are cost and cardiovascular evidence (Ozempic) and maximum A1C and weight reduction (Mounjaro), so most of the real decision comes down to which of those you weight more for your own diabetes.
What does the ProtocolPlus community actually do between the two?
This is the part no trial and no competitor page can give you: among users who have logged both brands, which one are people on, and which way do they move? Trial data tells you what each drug can do in a controlled study; it cannot tell you what real people decide once they have lived with both, watched their glucose meter, and seen the monthly cost. That is the gap our first-party data fills. The short version: the larger camp is on Mounjaro and the migration runs mostly one way toward it, but a stable, sizeable group stays on Ozempic for cost and heart-protection reasons.
Three numbers carry the story, all from ProtocolPlus app data among the roughly 6,600 users tracking one of these two:
- Adoption split: ~45% Ozempic, ~55% Mounjaro. Mounjaro is the larger camp, but it is not a blowout. Within the full ~11,400-user cohort, tirzepatide is 32% of all tracked compounds and semaglutide 26%.
- Co-tracking: ~16% (about 1,058 users) log both. These are people titrating across, comparing, or bridging supply gaps. Running both in sequence is common enough that "which one" is often really "which one first."
- Net switch favors Mounjaro ~2.5 to 1. About 34% of Ozempic users (roughly 1,008) later moved to or added Mounjaro, versus about 11% of Mounjaro users (roughly 401) who moved the other way. The net flow, around 607 users, points to Mounjaro.
Who the community is on now (and why Ozempic holds a large camp)
The reverse flow is small but real, and it tells you who Ozempic is still right for: people whose A1C is controlled without needing Mounjaro's extra push, people who value the cardiovascular evidence, and people for whom the price gap matters month after month. Switching is not a verdict that one drug is universally better. It is mostly people climbing toward the strongest A1C tool they can access and afford.
The timing of the typical switch is itself informative. The most common pattern is not "tried Ozempic briefly, bailed," but a switch after months on Ozempic, once A1C stalls above target near the top dose or weight loss flattens. That plateau, not intolerance, is the usual trigger, and the destination is usually a mid-tier Mounjaro dose rather than 15 mg right away, because the added GIP pathway often restarts progress. Clinicians generally move people across without a washout, since both are weekly injectables in the same class. None of that is a protocol you should run on your own, but it explains why the switch data leans the way it does.
Glycemic control: what the diabetes trials actually show
The one-sentence answer: in the only head-to-head diabetes trial, Mounjaro lowered A1C clearly more than Ozempic and got more people to target. SURPASS-2 randomized 1,879 adults with type 2 diabetes inadequately controlled on metformin to tirzepatide (5, 10, or 15 mg) or semaglutide 1 mg for 40 weeks. From a baseline A1C around 8.3%, tirzepatide cut A1C about 2.01, 2.24, and 2.30 points across its three doses, versus about 1.86 points for semaglutide 1 mg. The 15 mg arm beat semaglutide by roughly 0.45 points, a statistically significant and clinically meaningful gap for diabetes.
The averages hide the more useful story, which is how many people actually hit target. In SURPASS-2, about 79% of patients on tirzepatide 15 mg reached an A1C below 7% (the standard diabetes goal), versus about 64% on semaglutide 1 mg, and a striking share of tirzepatide patients reached A1C below 5.7% (the non-diabetic range) without raising hypoglycemia risk. If your goal is getting under 7% and staying there, that response gap is the practical difference.
One fair caveat: SURPASS-2 compared Mounjaro's full dose range against Ozempic at 1 mg, which was the top approved dose at the time but below the 2 mg dose later approved. At 2 mg, Ozempic lowers A1C more than at 1 mg, so the head-to-head gap at each drug's true maximum is somewhat narrower than the raw 2.30-versus-1.86 figures suggest. The direction of the result is robust, but treat the exact margin as the floor of the comparison, not a fixed law. The mechanism explains the edge either way: Ozempic activates the GLP-1 receptor, while Mounjaro adds a second agonist at the GIP receptor, and in most people the combined effect on glucose and appetite is additive rather than redundant. For the full pharmacology, see the semaglutide guide and the tirzepatide guide; for the molecule-level head-to-head, see semaglutide vs tirzepatide.
Weight loss: the crossover most people care about
The one-sentence answer: both brands cause meaningful weight loss as a side benefit of diabetes treatment, and Mounjaro causes clearly more. In SURPASS-2, Mounjaro 15 mg reduced body weight about 12.4 kg versus 6.2 kg for Ozempic 1 mg, roughly double, while both were treating diabetes rather than being prescribed for obesity.
This is the part that drives most of the real-world demand and most of the switching, because many people came for blood sugar and stayed for the scale. It is worth being precise about brands here, though: when weight loss is the primary, on-label goal, the relevant products are not Mounjaro and Ozempic but their weight-management siblings, Zepbound and Wegovy, which use the same molecules at obesity-specific doses. If your main question is which loses more weight as a dedicated weight-loss drug, that comparison lives on its own page. We keep this page focused on the diabetes brands and the weight that comes along with glucose control. See Zepbound vs Wegovy for the weight-management brands and best peptides for weight loss for the full field.
Cardiovascular and kidney evidence: Ozempic's strongest card
The one-sentence answer: Ozempic has the deeper proven heart-protection record in type 2 diabetes, which is the clearest reason to choose it over Mounjaro despite the A1C gap. Semaglutide carries an FDA cardiovascular-risk-reduction indication; tirzepatide does not yet.
The anchor is SUSTAIN-6, which randomized 3,297 adults with type 2 diabetes at high cardiovascular risk to semaglutide or placebo. Over a median 2.1 years, semaglutide cut the rate of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) by about 26% (hazard ratio 0.74), with the primary endpoint occurring in 6.6% of the semaglutide group versus 8.9% on placebo, driven largely by fewer strokes. That outcomes evidence is why Ozempic carries a formal cardiovascular indication and why many cardiologists favor it for a patient who already has heart disease.
Mounjaro's dedicated cardiovascular outcomes trial is still running, so as of 2026 it shows excellent surrogate markers (A1C, weight, blood pressure, and lipids all move in the right direction) but does not yet have the hard-endpoint proof Ozempic does. That is an important distinction: improving a risk marker is not the same as proving fewer heart attacks and strokes, which takes years of outcomes data to demonstrate. Most experts expect Mounjaro to show cardiovascular benefit too, given the surrogate signals, but expectation is not the same as evidence. For a diabetic patient whose main risk is the heart, that gap can reasonably decide the choice before A1C even enters the picture, while for someone without established heart disease it weighs less.
Cost and coverage with a diabetes diagnosis
The one-sentence answer: with a type 2 diabetes diagnosis both are often covered, but in our community data Ozempic costs roughly a third of Mounjaro per dose, and that gap is the single most common reason people stay on or retreat to Ozempic. Cost, not efficacy, is what keeps Ozempic's camp large.
In ProtocolPlus cost figures, semaglutide runs about a median $19 per dose versus about $56 for tirzepatide, roughly a three-to-one difference. Spread across a year of weekly injections, that is the kind of gap that changes behavior, and it shows up again and again as the trigger for the smaller reverse switch from Mounjaro back to Ozempic. Brand list prices without insurance are far higher for both (well over $1,000 a month at retail), and the real number a patient pays is dominated by coverage rather than list price. The good news for this comparison is that a type 2 diabetes diagnosis routes you to the diabetes brands, Ozempic and Mounjaro, which many plans cover with prior authorization, whereas obesity alone routes you to Wegovy or Zepbound, which are covered less consistently. We do not quote brand list prices here because they shift constantly and vary by pharmacy; treat the per-dose community figures as a directional signal, not a quote.
Tolerability: closer than the efficacy gap suggests
The one-sentence answer: both are GI-dominant and broadly similar to tolerate, so tolerability rarely decides this matchup. In SURPASS-2 the rates of nausea, diarrhea, and vomiting were in the same range across both drugs, and the same pattern shows up in community reports.
In our community data the most common effects line up almost on top of each other: nausea (Ozempic 44% vs Mounjaro 42%), decreased appetite (40% vs 42%), diarrhea (30% vs 33%), constipation (24% vs 26%), and vomiting (22% vs 20%). These are self-reported community frequencies, not trial incidence and not proof of cause, but the pattern is clear: neither brand is the obviously gentler choice. There is a subtle directionality experienced users describe: Ozempic complaints skew slightly toward nausea and constipation, Mounjaro a touch more toward diarrhea. The far bigger lever for either is titration speed, since most severe GI episodes cluster around dose increases, which is why slow escalation does more for tolerability than the choice of brand.
Both brands share the same serious but rare warnings, including a boxed warning for thyroid C-cell tumors based on rodent data, plus pancreatitis and gallbladder risks, and the usual caution about hypoglycemia when combined with insulin or sulfonylureas. For the complete tolerability breakdown and red-flag list, read semaglutide side effects and tirzepatide side effects. This page does not duplicate them.
The editorial scorecard (the "why," not the verdict)
The fit-score radar below rates each brand 1 to 5 on six dimensions. With equal weighting the two essentially tie (77 vs 77): Mounjaro leads on effectiveness, Ozempic leads on cost, and they match on evidence, safety, access, and speed. That tie is the honest summary. For diabetes specifically, weight the evidence dimension toward Ozempic's heart-outcomes record and the effectiveness dimension toward Mounjaro's A1C edge, then let your own priorities break the tie. The community usage data above, not this radar, is the headline signal.
Choose Ozempic if... / Choose Mounjaro if...
The decision rarely needs a coin flip. These two cards cover the great majority of diabetes cases.
Choose Ozempic if:
- You want the deepest cardiovascular-outcomes evidence in type 2 diabetes (the SUSTAIN-6 ~26% reduction in major cardiac events; Ozempic carries the CV-risk indication, Mounjaro does not yet).
- Cost matters month to month. At roughly $19 vs $56 per dose in our data, Ozempic is the value pick.
- Your A1C is only modestly above target and you do not need Mounjaro's larger glucose-lowering ceiling.
- An oral GLP-1 could matter (the molecule also exists as Rybelsus; tirzepatide is injectable only).
Choose Mounjaro if:
- Maximum A1C lowering is the priority. It beat Ozempic head-to-head in SURPASS-2 and got more people under 7%.
- Weight loss alongside diabetes control matters. Mounjaro roughly doubled the weight reduction in that diabetes trial.
- You have plateaued on Ozempic and want the added GIP pathway. This is the single most common move in our community data.
- You can absorb the higher per-dose cost for the bigger glycemic and weight result.
The honest verdict
For most people whose main question is "which controls type 2 diabetes better on average," Mounjaro is the answer: it wins on A1C and weight head-to-head, and the community votes with its feet, with the net switch running about 2.5 to 1 toward it. But Ozempic is not a runner-up so much as the better fit for a specific, large group, those who need the proven heart-protection evidence, want an oral route someday, or feel the cost gap. If you are choosing today and your A1C is stubbornly high, Mounjaro is the stronger glucose-lowering brand. If you have established heart disease or a tight budget, Ozempic is a completely defensible choice that nearly half of our community stays on by preference. Either way, the drug is one tool inside a clinician-supervised diabetes plan, not a decision to make from a comparison page alone.
To make it concrete, here is how the decision usually lands by situation:
- Stubbornly high A1C, want it down fast: Mounjaro (bigger head-to-head A1C drop, more people under 7%).
- Established heart disease: Ozempic (the proven cardiovascular-outcomes record from SUSTAIN-6).
- Tight monthly budget: Ozempic (about a third of the per-dose cost in our data).
- Plateaued on Ozempic near the top dose: switch to Mounjaro; this is the community's most common move.
- Want the most weight loss while treating diabetes: Mounjaro (roughly double the weight reduction in SURPASS-2).
- Needles are a real barrier: the semaglutide molecule has an oral form (Rybelsus); tirzepatide does not.
For the molecule-level science behind these brands, see semaglutide vs tirzepatide. For the weight-management brands of the same two molecules, see Zepbound vs Wegovy. To see where both rank against every option people use for fat loss, see best peptides for weight loss.
Frequently Asked Questions
Sources
- Frias JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes" (SURPASS-2). New England Journal of Medicine, 2021;385:503-515. DOI 10.1056/NEJMoa2107519. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
- Marso SP, Bain SC, Consoli A, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes" (SUSTAIN-6). New England Journal of Medicine, 2016;375:1834-1844. DOI 10.1056/NEJMoa1607141. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
- U.S. Food & Drug Administration. "FDA approves novel, dual-targeted treatment for type 2 diabetes" (Mounjaro, tirzepatide). May 2022. Retrieved 2026-06-18. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes
- U.S. Food & Drug Administration. "Ozempic (semaglutide) injection prescribing information" (type 2 diabetes approval 2017; cardiovascular-risk reduction indication). Retrieved 2026-06-18. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
- Eli Lilly and Company. "Lilly's SURPASS-2 results published in The New England Journal of Medicine" (tirzepatide vs semaglutide A1C and weight). 2021. Retrieved 2026-06-18. https://investor.lilly.com/news-releases/news-release-details/lillys-surpass-2-results-published-new-england-journal-medicine
- ProtocolPlus. "Community head-to-head data: semaglutide (Ozempic) vs tirzepatide (Mounjaro)" (head-to-head/semaglutide__tirzepatide.json). First-party app data, 2026. n ~ 6,612 users tracking one of the two. Usage and switching signal, not a clinical efficacy verdict.